Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data
| dc.rights.license | open | en_US |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | KOROBELNIK, Jean-Francois
ORCID: 0000-0002-4438-9535 IDREF: 028739272 | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | DELCOURT, Cecile
ORCID: 0000-0002-2099-0481 IDREF: 035105291 | |
| dc.contributor.author | CREUZOT-GARCHER, Catherine | |
| dc.contributor.author | MELAINE, Asma | |
| dc.contributor.author | CHASSETUILLIER, Jules | |
| dc.contributor.author | LEJEUNE, Anne | |
| dc.contributor.author | BENARD, Steve | |
| dc.contributor.author | DUPONT-BENJAMIN, Laure | |
| dc.date.accessioned | 2021-10-04T09:02:51Z | |
| dc.date.available | 2021-10-04T09:02:51Z | |
| dc.date.issued | 2021-08-23 | |
| dc.identifier.issn | 1369-6998 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/112537 | |
| dc.description.abstractEn | AIMS: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is standard care for neovascular age-related macular degeneration (nAMD), but the recommended monthly injection regimen is burdensome. Evidence suggests low injection/monitoring frequencies in clinical practice and suboptimal vision outcomes. This observational cohort study uses administrative claims data from the French national healthcare system to assess anti-VEGF treatment patterns and nAMD-specific healthcare resource demands and costs. PATIENTS AND METHODS: nAMD patients ≥50 years initiating intravitreal ranibizumab, aflibercept or bevacizumab treatment (2014‒2015), and propensity score-matched non-nAMD patients (controls), were identified from the Echantillon Généraliste de Bénéficiaires database. Outcomes of interest included anti-VEGF treatment patterns, and healthcare resource utilization and associated costs of patients vis-à-vis controls over 24 months. RESULTS: Study patients (n = 355) received (mean) 5.2 and 2.4 anti-VEGF injections over 0‒12 and 12‒24 months, respectively. Most patients (79.0%) remained on their initial anti-VEGF agent; among treatment switchers the most common transition was from ranibizumab to aflibercept. During follow-up, nAMD patients were more likely than controls to require ophthalmology visits (99.7% vs 44.8%), ocular procedures (optical coherence tomography/angiography/fundoscopy) (96.9% vs 27.2%), cataract surgery (13.0% vs 6.7%), and medical transports (38.0% vs 31.9%). Mean numbers of ophthalmology visits (25.1 vs 1.2) and medical transports (6.0 vs 3.5) were higher (p<.01) among nAMD patients. Total reimbursed costs were two-fold higher for nAMD patients than controls (mean €16,799 vs €8255) due to higher treatment costs (€6847 vs €1156), medical fees (€1858 vs €295), hospital fees (€6396 vs €5235), and transport costs (€358 vs €259). Excess total healthcare cost was (mean) €5279 and €7918 over the first 12 and 24 months of treatment, respectively. CONCLUSIONS: Current intravitreal anti-VEGF treatment and monitoring requirements place considerable economic burden on the French healthcare system. New intravitreal therapies with extended dosing intervals and predictable efficacy might reduce demand on ophthalmology services. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
| dc.subject.en | Ophthalmology | |
| dc.subject.en | Neovascular age-related macular degeneration | |
| dc.subject.en | Intravitreal | |
| dc.subject.en | Anti-VEGF | |
| dc.subject.en | Retrospective | |
| dc.subject.en | Observational study | |
| dc.subject.en | Healthcare utilization | |
| dc.subject.en | Cost | |
| dc.subject.en | France | |
| dc.title.en | Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1080/13696998.2021.1971416 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 34420480 | en_US |
| bordeaux.journal | Journal of Medical Economics | en_US |
| bordeaux.page | 1-37 | en_US |
| bordeaux.volume | 24 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 1 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | LEHA_BPH | |
| bordeaux.team | LEHA_BPH | |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Allergan | en_US |
| hal.export | false | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Medical%20Economics&rft.date=2021-08-23&rft.volume=24&rft.issue=1&rft.spage=1-37&rft.epage=1-37&rft.eissn=1369-6998&rft.issn=1369-6998&rft.au=KOROBELNIK,%20Jean-Francois&DELCOURT,%20Cecile&CREUZOT-GARCHER,%20Catherine&MELAINE,%20Asma&CHASSETUILLIER,%20Jules&rft.genre=article |
